NCT03914612 · OUTCOME

Incidence of Pembrolizumab Treatment and Self-reported Neurotoxicity

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · Source last updated 2026-07-31

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 0-54 weeks from start of treatment

What was measured

Patient-reported neurotoxicity will be measured with FACT/GOG-Ntx subscale (short form).

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Patient-reported neurotoxicity will be measured with FACT/GOG-Ntx subscale (short form).
reporting Status: NOT_POSTED
time Frame: 0-54 weeks from start of treatment
title: Incidence of Pembrolizumab Treatment and Self-reported Neurotoxicity
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice